-
1
-
-
58149255300
-
Fact Sheet No. 312 - Diabetes
-
Fact Sheet No. 312 - Diabetes. , http://www.who.int/mediacentre/factsheets/fs312/en/
-
-
-
-
2
-
-
40249120466
-
Standards of medical care in diabetes-2008
-
American Diabetes Association
-
American Diabetes Association Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl 1):S12-S54. American Diabetes Association.
-
(2008)
Diabetes Care
, vol.31
, Issue.SUPPL 1
-
-
-
3
-
-
35148892823
-
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
-
10.1093/eurheartj/ehm316, 17726041
-
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Hellemans I, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007, 28:2375-2414. 10.1093/eurheartj/ehm316, 17726041.
-
(2007)
Eur Heart J
, vol.28
, pp. 2375-2414
-
-
Graham, I.1
Atar, D.2
Borch-Johnsen, K.3
Boysen, G.4
Burell, G.5
Cifkova, R.6
Dallongeville, J.7
De Backer, G.8
Ebrahim, S.9
Gjelsvik, B.10
Herrmann-Lingen, C.11
Hoes, A.12
Humphries, S.13
Knapton, M.14
Perk, J.15
Priori, S.G.16
Pyorala, K.17
Reiner, Z.18
Ruilope, L.19
Sans-Menendez, S.20
Scholte op Reimer, W.21
Weissberg, P.22
Wood, D.23
Yarnell, J.24
Zamorano, J.L.25
Walma, E.26
Fitzgerald, T.27
Cooney, M.T.28
Dudina, A.29
Vahanian, A.30
Camm, J.31
De Caterina, R.32
Dean, V.33
Dickstein, K.34
Funck-Brentano, C.35
Filippatos, G.36
Hellemans, I.37
Kristensen, S.D.38
McGregor, K.39
Sechtem, U.40
Silber, S.41
Tendera, M.42
Widimsky, P.43
Zamorano, J.L.44
Hellemans, I.45
Altiner, A.46
Bonora, E.47
Durrington, P.N.48
Fagard, R.49
Giampaoli, S.50
Hemingway, H.51
Hakansson, J.52
Kjeldsen, S.E.53
Larsen, M.L.54
Mancia, G.55
Manolis, A.J.56
Orth-Gomer, K.57
Pedersen, T.58
Rayner, M.59
Ryden, L.60
Sammut, M.61
Schneiderman, N.62
Stalenhoef, A.F.63
Tokgözoglu, L.64
Wiklund, O.65
Zampelas, A.66
more..
-
4
-
-
0024523898
-
Hepatic glucose production and insulin sensitivity preceding diabetes in monkeys
-
Bodkin NL, Metzger BL, Hansen BC. Hepatic glucose production and insulin sensitivity preceding diabetes in monkeys. Am J Physiol 1989, 256:E676-E681.
-
(1989)
Am J Physiol
, vol.256
-
-
Bodkin, N.L.1
Metzger, B.L.2
Hansen, B.C.3
-
5
-
-
0029092395
-
Pancreatic pathology in non-insulin dependent diabetes (NIDDM)
-
10.1016/0168-8227(95)01075-O, 8529518
-
Clark A, de Koning EJ, Hattersley AT, Hansen BC, Yajnik CS, Poulton J. Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res Clin Pract 1995, 28(Suppl):S39-S47. 10.1016/0168-8227(95)01075-O, 8529518.
-
(1995)
Diabetes Res Clin Pract
, vol.28
, Issue.SUPPL
-
-
Clark, A.1
de Koning, E.J.2
Hattersley, A.T.3
Hansen, B.C.4
Yajnik, C.S.5
Poulton, J.6
-
6
-
-
0022868041
-
Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey
-
10.1007/BF00870281, 3542671
-
Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 1986, 29:713-719. 10.1007/BF00870281, 3542671.
-
(1986)
Diabetologia
, vol.29
, pp. 713-719
-
-
Hansen, B.C.1
Bodkin, N.L.2
-
7
-
-
0025182175
-
Beta-cell hyperresponsiveness: earliest event in development of diabetes in monkeys
-
Hansen BC, Bodkin NL. Beta-cell hyperresponsiveness: earliest event in development of diabetes in monkeys. Am J Physiol 1990, 259:R612-R617.
-
(1990)
Am J Physiol
, vol.259
-
-
Hansen, B.C.1
Bodkin, N.L.2
-
8
-
-
26844515620
-
Decreased hepatic insulin extraction precedes overt noninsulin dependent (type II) diabetes in obese monkeys
-
Hansen BC, Striffler JS, Bodkin NL. Decreased hepatic insulin extraction precedes overt noninsulin dependent (type II) diabetes in obese monkeys. Obes Res 1993, 1:252-260.
-
(1993)
Obes Res
, vol.1
, pp. 252-260
-
-
Hansen, B.C.1
Striffler, J.S.2
Bodkin, N.L.3
-
9
-
-
34248402754
-
Primate models of type 2 diabetes
-
Philadelphia: Lippincott, Williams & Wilkins, LeRoith D, Olefsky JM, Taylor SI, 3
-
Hansen BC. Primate models of type 2 diabetes. Diabetes Mellitus: A Fundamental and Clinical Text 2004, 1059-1074. Philadelphia: Lippincott, Williams & Wilkins, LeRoith D, Olefsky JM, Taylor SI, 3.
-
(2004)
Diabetes Mellitus: A Fundamental and Clinical Text
, pp. 1059-1074
-
-
Hansen, B.C.1
-
10
-
-
47249135708
-
The rhesus monkey (Macaca mulatta) manifests all features of human type 2 diabetes
-
New York: CRC Press, Shafrir E, 2
-
Tigno XT, Hansen BC. The rhesus monkey (Macaca mulatta) manifests all features of human type 2 diabetes. Animal Models of Diabetes: Frontiers in Research 2007, 251-270. New York: CRC Press, Shafrir E, 2., http://www.crcpress.com/product/isbn/9780849395345
-
(2007)
Animal Models of Diabetes: Frontiers in Research
, pp. 251-270
-
-
Tigno, X.T.1
Hansen, B.C.2
-
11
-
-
79851507923
-
Chronomics of the metabolic syndrome
-
Totowa, New Jersey: Humana Press, Hansen BC, Bray GA
-
Hansen BC. Chronomics of the metabolic syndrome. The Metabolic Syndrome: Epidemiology, Clinical Treatment, and Underlying Mechanisms 2008, 373-386. Totowa, New Jersey: Humana Press, Hansen BC, Bray GA.
-
(2008)
The Metabolic Syndrome: Epidemiology, Clinical Treatment, and Underlying Mechanisms
, pp. 373-386
-
-
Hansen, B.C.1
-
12
-
-
34248381376
-
Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus
-
10.1016/j.metabol.2007.01.015, 17512318
-
Ding SY, Tigno XT, Hansen BC. Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus. Metabolism 2007, 56:838-846. 10.1016/j.metabol.2007.01.015, 17512318.
-
(2007)
Metabolism
, vol.56
, pp. 838-846
-
-
Ding, S.Y.1
Tigno, X.T.2
Hansen, B.C.3
-
13
-
-
0037338615
-
Mortality and Morbidity in laboratory-maintained rhesus monkeys and effects of long-term dietary restriction
-
Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E, Hansen BC. Mortality and Morbidity in laboratory-maintained rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci 2003, 58(3):212-219.
-
(2003)
J Gerontol A Biol Sci
, vol.58
, Issue.3
, pp. 212-219
-
-
Bodkin, N.L.1
Alexander, T.M.2
Ortmeyer, H.K.3
Johnson, E.4
Hansen, B.C.5
-
14
-
-
34548780737
-
A novel peroxisome proliferator-activated receptor α/γ dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys
-
10.1016/j.metabol.2007.05.019, 17884441
-
Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator-activated receptor α/γ dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 2007, 56:1334-1339. 10.1016/j.metabol.2007.05.019, 17884441.
-
(2007)
Metabolism
, vol.56
, pp. 1334-1339
-
-
Ding, S.Y.1
Tigno, X.T.2
Braileanu, G.T.3
Ito, K.4
Hansen, B.C.5
-
15
-
-
0028144529
-
Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys
-
10.2337/diabetes.43.2.204, 8288044
-
Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 1994, 43:204-211. 10.2337/diabetes.43.2.204, 8288044.
-
(1994)
Diabetes
, vol.43
, pp. 204-211
-
-
Kemnitz, J.W.1
Elson, D.F.2
Roecker, E.B.3
Baum, S.T.4
Bergman, R.N.5
Meglasson, M.D.6
-
16
-
-
33846418834
-
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
-
10.1210/en.2006-1168, 17068132
-
Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781. 10.1210/en.2006-1168, 17068132.
-
(2007)
Endocrinology
, vol.148
, pp. 774-781
-
-
Kharitonenkov, A.1
Wroblewski, V.J.2
Koester, A.3
Chen, Y.F.4
Clutinger, C.K.5
Tigno, X.T.6
Hansen, B.C.7
Shanafelt, A.B.8
Etgen, G.J.9
-
17
-
-
0035942162
-
A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
-
10.1073/pnas.091021198, 33205, 11309497
-
Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001, 98:5306-5311. 10.1073/pnas.091021198, 33205, 11309497.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 5306-5311
-
-
Oliver, W.R.1
Shenk, J.L.2
Snaith, M.R.3
Russell, C.S.4
Plunket, K.D.5
Bodkin, N.L.6
Lewis, M.C.7
Winegar, D.A.8
Sznaidman, M.L.9
Lambert, M.H.10
Xu, H.E.11
Sternbach, D.D.12
Kliewer, S.A.13
Hansen, B.C.14
Willson, T.M.15
-
18
-
-
0034753632
-
Effects of fenofibrate on lipid parameters in obese rhesus monkeys
-
Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WQ, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001, 42:1543-1551.
-
(2001)
J Lipid Res
, vol.42
, pp. 1543-1551
-
-
Winegar, D.A.1
Brown, P.J.2
Wilkison, W.O.3
Lewis, M.C.4
Ott, R.J.5
Tong, W.Q.6
Brown, H.R.7
Lehmann, J.M.8
Kliewer, S.A.9
Plunket, K.D.10
Way, J.M.11
Bodkin, N.L.12
Hansen, B.C.13
-
19
-
-
19344375843
-
Skeletal muscle glycogen synthase subcellular localization: effects of insulin and PPAR-α agonist (K-111) administration in rhesus monkeys
-
Ortmeyer HK, Adall Y, Marciani KR, Katsiaras A, Ryan AS, Bodkin NL, Hansen BC. Skeletal muscle glycogen synthase subcellular localization: effects of insulin and PPAR-α agonist (K-111) administration in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1509-R1517.
-
(2005)
Am J Physiol Regul Integr Comp Physiol
, vol.288
-
-
Ortmeyer, H.K.1
Adall, Y.2
Marciani, K.R.3
Katsiaras, A.4
Ryan, A.S.5
Bodkin, N.L.6
Hansen, B.C.7
-
20
-
-
2942573031
-
Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)α activator, in non-human primates
-
Schäfer SA, Hansen BC, Völkl A, Fahimi HD, Pill J. Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)α activator, in non-human primates. Biochem Pharmacol 2004, 68:239-251.
-
(2004)
Biochem Pharmacol
, vol.68
, pp. 239-251
-
-
Schäfer, S.A.1
Hansen, B.C.2
Völkl, A.3
Fahimi, H.D.4
Pill, J.5
-
21
-
-
0344586732
-
The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys
-
10.1055/s-2003-43510, 14605998
-
Bodkin NL, Pill J, Meyer K, Hansen BC. The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. Horm Metab Res 2003, 35:617-624. 10.1055/s-2003-43510, 14605998.
-
(2003)
Horm Metab Res
, vol.35
, pp. 617-624
-
-
Bodkin, N.L.1
Pill, J.2
Meyer, K.3
Hansen, B.C.4
-
22
-
-
64249155573
-
Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes
-
Bénardeau A, Benz J, Binggeli A, Blum D, Boehringer M, Grether U, Hilpert H, Kuhn B, Märki HP, Meyer M, Püntener K, Raab S, Ruf A, Schlatter D, Mohr P. Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes. Bioorg Med Chem Lett 2009, 19:2468-2473.
-
(2009)
Bioorg Med Chem Lett
, vol.19
, pp. 2468-2473
-
-
Bénardeau, A.1
Benz, J.2
Binggeli, A.3
Blum, D.4
Boehringer, M.5
Grether, U.6
Hilpert, H.7
Kuhn, B.8
Märki, H.P.9
Meyer, M.10
Püntener, K.11
Raab, S.12
Ruf, A.13
Schlatter, D.14
Mohr, P.15
-
23
-
-
33748672081
-
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis
-
10.1517/14728214.11.3.379, 16939380
-
Pourcet B, Fruchart JC, Staels B, Glineur C. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 2006, 11:379-401. 10.1517/14728214.11.3.379, 16939380.
-
(2006)
Expert Opin Emerg Drugs
, vol.11
, pp. 379-401
-
-
Pourcet, B.1
Fruchart, J.C.2
Staels, B.3
Glineur, C.4
-
24
-
-
28144451163
-
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
-
10.1001/jama.294.20.joc50147, 16239637
-
Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294:2581-2586. 10.1001/jama.294.20.joc50147, 16239637.
-
(2005)
JAMA
, vol.294
, pp. 2581-2586
-
-
Nissen, S.E.1
Wolski, K.2
Topol, E.J.3
-
25
-
-
34548182594
-
PPAR dual agonists: are they opening Pandora's Box?
-
10.1016/j.phrs.2007.03.002, 17428674
-
Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box?. Pharmacol Res 2007, 56:91-98. 10.1016/j.phrs.2007.03.002, 17428674.
-
(2007)
Pharmacol Res
, vol.56
, pp. 91-98
-
-
Balakumar, P.1
Rose, M.2
Ganti, S.S.3
Krishan, P.4
Singh, M.5
-
26
-
-
27444443876
-
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
-
10.1161/CIRCULATIONAHA.105.169404, 16157765
-
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
-
(2005)
Circulation
, vol.112
, pp. 2735-2752
-
-
Grundy, S.M.1
Cleeman, J.I.2
Daniels, S.R.3
Donato, K.A.4
Eckel, R.H.5
Franklin, B.A.6
Gordon, D.J.7
Krauss, R.M.8
Savage, P.J.9
Smith, S.C.10
Spertus, J.A.11
Costa, F.12
-
27
-
-
0003633755
-
-
Washington, DC National Academy Press, Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council
-
Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council Guide for the Care and Use of Laboratory Animals 1996, Washington, DC National Academy Press, Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council.
-
(1996)
Guide for the Care and Use of Laboratory Animals
-
-
-
28
-
-
0036210564
-
Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
-
Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002, 48:171-180.
-
(2002)
Clin Lab
, vol.48
, pp. 171-180
-
-
Otvos, J.D.1
-
29
-
-
0026644250
-
Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement
-
Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
-
(1992)
Clin Chem
, vol.38
, pp. 1632-1638
-
-
Otvos, J.D.1
Jeyarajah, E.J.2
Bennett, D.W.3
Krauss, R.M.4
-
30
-
-
0348110533
-
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus
-
10.1016/j.amjmed.2003.08.011, 14678862
-
Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003, 115(Suppl 8A):24S-28S. 10.1016/j.amjmed.2003.08.011, 14678862.
-
(2003)
Am J Med
, vol.115
, Issue.SUPPL 8A
-
-
Brunzell, J.D.1
Ayyobi, A.F.2
-
31
-
-
0037317156
-
Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance
-
10.2337/diabetes.52.2.453, 12540621
-
Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462. 10.2337/diabetes.52.2.453, 12540621.
-
(2003)
Diabetes
, vol.52
, pp. 453-462
-
-
Garvey, W.T.1
Kwon, S.2
Zheng, D.3
Shaughnessy, S.4
Wallace, P.5
Hutto, A.6
Pugh, K.7
Jenkins, A.J.8
Klein, R.L.9
Liao, Y.10
-
32
-
-
67649839953
-
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
-
10.1016/S0140-6736(09)60870-9, 19515415
-
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135. 10.1016/S0140-6736(09)60870-9, 19515415.
-
(2009)
Lancet
, vol.374
, pp. 126-135
-
-
Henry, R.R.1
Lincoff, A.M.2
Mudaliar, S.3
Rabbia, M.4
Chognot, C.5
Herz, M.6
-
33
-
-
78650262266
-
Insulin signaling and insulin sensitizing in muscle and liver of obese monkeys: PPARγ agonist improves defective activation of atypical protein kinase C
-
10.1089/ars.2010.3234, 20518698
-
Ortmeyer HK, Sajan MP, Miura A, Kanoh Y, Rivas J, Li Y, Standaert ML, Ryan A, Bodkin NL, Farese RV, Hansen BC. Insulin signaling and insulin sensitizing in muscle and liver of obese monkeys: PPARγ agonist improves defective activation of atypical protein kinase C. Antioxid Redox Signal 2011, 14(2):207-19. 10.1089/ars.2010.3234, 20518698.
-
(2011)
Antioxid Redox Signal
, vol.14
, Issue.2
, pp. 207-219
-
-
Ortmeyer, H.K.1
Sajan, M.P.2
Miura, A.3
Kanoh, Y.4
Rivas, J.5
Li, Y.6
Standaert, M.L.7
Ryan, A.8
Bodkin, N.L.9
Farese, R.V.10
Hansen, B.C.11
-
34
-
-
22144492005
-
Effects of peroxisome proliferator-activated receptor α/δ agonists on HDL-cholesterol in vervet monkeys
-
10.1194/jlr.M500002-JLR200, 15716581
-
Wallace JM, Schwarz M, Coward P, Houze J, Sawyer JK, Kelley KL, Chai A, Rudel LL. Effects of peroxisome proliferator-activated receptor α/δ agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 2005, 46:1009-1016. 10.1194/jlr.M500002-JLR200, 15716581.
-
(2005)
J Lipid Res
, vol.46
, pp. 1009-1016
-
-
Wallace, J.M.1
Schwarz, M.2
Coward, P.3
Houze, J.4
Sawyer, J.K.5
Kelley, K.L.6
Chai, A.7
Rudel, L.L.8
-
35
-
-
0346219295
-
Effect of thiazolidinediones on body weight in patients with diabetes mellitus
-
10.1016/j.amjmed.2003.09.005, 14678865
-
Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003, 115(Suppl 8A):42S-48S. 10.1016/j.amjmed.2003.09.005, 14678865.
-
(2003)
Am J Med
, vol.115
, Issue.SUPPL 8A
-
-
Fonseca, V.1
-
36
-
-
68849088748
-
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease
-
Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovas Diabetol 2009, 8:38.
-
(2009)
Cardiovas Diabetol
, vol.8
, pp. 38
-
-
Fisman, E.Z.1
Tenenbaum, A.2
|